Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Liabilities and Shareholders Equity (2021 - 2026)

Atara Biotherapeutics filings provide 6 years of Liabilities and Shareholders Equity readings, the most recent being $20.0 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity fell 67.77% to $20.0 million in Q1 2026 year-over-year; TTM through Mar 2026 was $107.3 million, a 75.11% decrease, with the full-year FY2025 number at $20.2 million, down 81.45% from a year prior.
  • Liabilities and Shareholders Equity hit $20.0 million in Q1 2026 for Atara Biotherapeutics, down from $20.2 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $436.1 million in Q2 2022 to a low of $20.0 million in Q1 2026.
  • Median Liabilities and Shareholders Equity over the past 5 years was $165.3 million (2024), compared with a mean of $187.3 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: dropped 19.59% in 2022 and later crashed 81.45% in 2025.
  • Atara Biotherapeutics' Liabilities and Shareholders Equity stood at $376.4 million in 2022, then tumbled by 56.03% to $165.5 million in 2023, then crashed by 34.08% to $109.1 million in 2024, then crashed by 81.45% to $20.2 million in 2025, then fell by 1.18% to $20.0 million in 2026.
  • The last three reported values for Liabilities and Shareholders Equity were $20.0 million (Q1 2026), $20.2 million (Q4 2025), and $30.2 million (Q3 2025) per Business Quant data.